Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 32, 06 March 2024
Open
Access | Article
Current common prodrug delivery methods and biochemical property
* Author to whom correspondence should be addressed.
Abstract
Prodrugs are pivotal in overcoming drug delivery and absorption challenges. These bioreversible derivatives are strategically designed to address medicines’ poor bioavailability and administration constraints. Prodrugs offer versatile solutions for various delivery methods, including oral, dermal, nasal, and central nervous system (CNS) routes and tumor targeting. This literature review aims to summarize several prodrugs delivery methods. The report also focuses on the common concepts of prodrug design. The utilization of prodrugs also includes innovative strategies, such as receptor-mediated internalization and responsive drug release, demonstrating promising outcomes for cancer therapy. The application of prodrug methods is comprehensive. Prodrugs emerged as a universal approach to improve drug administration and absorption, with their applications spanning diverse medical contexts. By tailoring prodrugs to specific delivery routes and addressing unique challenges, researchers open avenues for more effective and targeted therapies. Further exploration and optimization of prodrug strategies hold the potential to revolutionize drug delivery in clinical settings. Although prodrugs have many advantages, there are still many possible future improvements. Many diseases or target organs still need help applying prodrugs even though the current drug design needs this technology for administration. Future research should focus on the lack of chemical stability, including considering the balance between aqueous solubility and lipophilicity. Also, the elimination of the formation of degradation by-products or the design of acceptable metabolism pathways is another aspect that should be considered.
Keywords
Prodrug, drug delivery, lipophilicity, aqueous solubility
References
1. Jarkko Rautio HK, Tycho Heimbach, Reza Oliyai, Dooman Oh, Tomi Järvinen and Jouko Savolainen. Prodrugs: design and clinical applications. 2008;7.
2. Yanxiu Ge YM, Lingbing Li. The application of prodrug-based nano-drug delivery strategy in cancer combination therapy. 2016.
3. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. 2000.
4. Valentino J. Stella KWN-A. Prodrug strategies to overcome poor water solubility. 2007.
5. Fred Y Aoki KED. Oseltamivir: a clinical and pharmacological perspective. 2001.
6. Antiviral prodrugs-the development of
7. Jarkko Rautio * TN, Hannu Taipale , Jouko Vepsalainen , Jukka Gynther , a a Krista Laine , Tomi Jarvinen. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. 2000.
8. FRANCESCO PAOLO BONINA MGR, LUCIA AVALLONE, FRANCESCO BARBATO, MARZIA AMATO, CARMELO PUGLIA, MAURIZIO RICCI, PAOLO DE CAPRARIIS. New Oligoethylene Ester Derivatives of 5-Iodo-20-deoxyuridine as Dermal Prodrugs: Synthesis, Physicochemical Properties, and Skin Permeation Studies. 2001.
9. C.R. Behl HKP, A.P. Sileno, J. deMeireles, V.D. Romeo. Effects of physicochemical properties and other factors on systemic nasal drug delivery. 1997.
10. Giridhar S Tirucherai CYAKM. Prodrugs in nasal drug delivery. 2001.
11. Abdur Rauf Khan ML, Muhammad Wasim Khan, Guangxi Zhai. Progress in brain targeting drug delivery system by nasal route. 2017.
12. N. Joan Abbott AAKP, Diana E.M. Dolman, Siti R. Yusof, David J. Begley. Structure and function of the blood–brain barrier. 2010.
13. Pardridge WM. Why is the global CNS pharmaceutical market so under-penetrated? 2002.
14. Jarkko Rautio KL, Mikko Gynther, Jouko Savolainen. Prodrug Approaches for CNS Delivery. 2008.
15. Nigel H. Greig SG, Eileen M. Daly, Daniel J. Sweeney, and Stanley I. Rapoport. Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. 1990.
16. Vincenzo Quagliariello AG, Som Akshay Jain, Francesco Rosso, Rosario Vincenzo Iaffaioli, Alfonso Barbarisi, Manlio Barbarisi, Nicola Tirelli. Double-responsive hyaluronic acid-based prodrugs for efficient tumour targeting. 2021.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-321-0
- ISBN (Online)
- 978-1-83558-322-7
- Published Date
- 06 March 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/32/20240798
- Copyright
- 06 March 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited